Log in with your email address username.


[Comment] Towards interferon-free treatment for all HCV genotypes

It is surely unique in modern medicine that regulatory agencies should approve seven new compounds to treat a specific disease within just 12 months. The European Commission granted marketing authorisation for sofosbuvir, a nucleotide hepatitis C virus (HCV) polymerase inhibitor, in January, 2014. Since then, the HCV protease inhibitor simeprevir (May, 2014), the NS5A inhibitor daclatasvir (August, 2014), and the single-tablet combination of the HCV NS5 inhibitor ledipasvir with sofosbuvir (November, 2014) have reached the market; followed most recently by the three-drug combination of ombitasvir (NS5A inhibitor), the ritonavir-boosted protease inhibitor paritaprevir, and the first non-nucleosidic polymerase inhibitor dasabuvir (January, 2015).